Driving better healthcare through innovation
Watch our company video to learn about who we are and what we do. From being founded by Dr Geoffrey Grigg in 2001, the company has grown to offer a range of syndromic testing solutions with our EasyScreenTM products, supporting hospital and pathology laboratories worldwide with our unique 3baseTM technology.
Transforming Molecular Diagnostics
We focus on the development and commercialisation of our proprietary platform technology, 3base™.
Genetic Signatures has released a suite of real-time PCR based products for the routine detection of infectious diseases under the EasyScreen™ brand . This proprietary MDx technology provides hospitals and pathology laboratories with the ability to screen for a wide array of infectious pathogens with a high degree of specificity in a rapid throughput (time to result) environment.
3base™ Multiplex Technology
Compatible with non-molecular laboratories, using a universal extraction process regardless of sample type, and with the ability to perform multi-batch assays.
A standardized work-flow solution that caters to both high and medium throughput laboratories without compromising pathogen detection.
Currently offering over 100 pathogen targets across Enteric, Respiratory, Antimicrobial Resistance, Sexual Health, Tropical Diseases, and Viral Meningitis.
Genetic Signatures is transforming molecular diagnostics via streamlined sample processing methods linked to highly multiplexed real-time PCR screening assays.
Our automated single universal sample preparation method is suitable for bacterial, protozoan or viral (DNA & RNA) targets.
The EasyScreen™ Detection Kits simultaneously detect a larger number of pathogen targets in a shorter time than conventional methods.
Genetic Signatures is a molecular diagnostic (MDx) company focused on the development and commercialisation of its proprietary 3base™ platform technology. Our aim is to become a global leader in the supply of diagnostic solutions for the rapid detection of infectious diseases to enable faster treatment and facilitate improved patient outcomes.